Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.

Banks PD, Lasocki A, Lau PKH, Sandhu S, McArthur G, Shackleton M.

Health Sci Rep. 2019 Feb 1;2(3):e115. doi: 10.1002/hsr2.115. eCollection 2019 Mar.

2.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ.

Ann Oncol. 2019 May 1;30(5):804-814. doi: 10.1093/annonc/mdz048.

PMID:
30838379
3.

Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma.

Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, McIntosh L, Mitchell KA, Shaw E, Rizos H, Long GV, Hayward N, McArthur GA, Papenfuss AT, Harvey KF, Shackleton M.

Mol Cancer Res. 2019 Jul;17(7):1435-1449. doi: 10.1158/1541-7786.MCR-18-0407. Epub 2019 Mar 4.

PMID:
30833299
4.

Macroinvertebrate Responses to Conductivity in Different Bioregions of Victoria, Australia.

Shackleton M, Holland A, Stitz L, McInerney P.

Environ Toxicol Chem. 2019 Jun;38(6):1334-1342. doi: 10.1002/etc.4400. Epub 2019 May 9.

PMID:
30790341
5.

Personalised surveillance after treatment for high-risk cancer.

Guo C, Lewin J, Shackleton M.

Oncotarget. 2019 Jan 22;10(7):694-695. doi: 10.18632/oncotarget.26619. eCollection 2019 Jan 22. No abstract available.

6.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM.

Pigment Cell Melanoma Res. 2019 Jul;32(4):553-563. doi: 10.1111/pcmr.12775. Epub 2019 Mar 3.

PMID:
30767428
7.

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.

Eur J Cancer. 2018 Dec;105:88-102. doi: 10.1016/j.ejca.2018.09.027. Epub 2018 Nov 13.

PMID:
30439628
8.

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.

Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, Herschtal A, Spillane J, Gyorki D, Speakman D, Estall V, Donahoe S, Pohl M, Pope K, Chua M, Sandhu S, McArthur GA, McCormack CJ, Henderson M, Hicks RJ, Shackleton M.

Ann Oncol. 2018 Jul 1;29(7):1569-1574. doi: 10.1093/annonc/mdy124.

PMID:
29659679
9.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
10.

Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma.

Noguchi F, Inui S, Fedele C, Shackleton M, Itami S.

Mol Cancer Ther. 2017 May;16(5):936-947. doi: 10.1158/1535-7163.MCT-15-0235. Epub 2017 Feb 21.

11.

Current issues involved with the identification and nutritional value of wood grubs consumed by Australian Aborigines.

Yen A, Bilney C, Shackleton M, Lawler S.

Insect Sci. 2018 Apr;25(2):199-210. doi: 10.1111/1744-7917.12430. Epub 2017 Mar 14. Review.

PMID:
27990779
12.

Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.

Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Frankel AE, Johnson TM, DeBerardinis RJ, Morrison SJ.

Nat Commun. 2016 Sep 29;7:13080. doi: 10.1038/ncomms13080. No abstract available.

13.

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, Gamell C, Haupt Y.

Oncogene. 2016 Dec 1;35(48):6235-6245. doi: 10.1038/onc.2016.159. Epub 2016 Sep 19.

PMID:
27641331
14.

A community-based model of rapid autopsy in end-stage cancer patients.

Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, Devereux L, O'Brien P, Gunawardena S, Hampson C, Strachan K, Jaravaza RD, Francis V, Young G, Ranson D, Samaranayake R, Stevens D, Boyle S, Fedele C, Topp M, Ho G, Teo ZL, Taylor RA, Papargiris MM, Lawrence MG, Wang H, Risbridger GP, Haynes NM, Medon M, Johnstone RW, Vidacs E, Arnau GM, Vergara IA, Papenfuss AT, McArthur G, Waring P, Carvosso S, Angel C, Gyorki D, Solomon B, Mitchell G, Shanley S, Francis PA, Dawson SJ, Haffenden A, Tidball E, Volchek M, Pyman J, Madadin M, Leditschke J, Cordner S; Melbourne Melanoma Project; Australian Ovarian Cancer Study Group (AOCS); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Shackleton M, Bowtell DD.

Nat Biotechnol. 2016 Oct;34(10):1010-1014. doi: 10.1038/nbt.3674. Epub 2016 Sep 12. No abstract available.

PMID:
27617737
15.

Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.

Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Johnson TM, DeBerardinis RJ, Morrison SJ.

Nat Commun. 2016 Aug 22;7:12336. doi: 10.1038/ncomms12336.

16.

The Trichoptera barcode initiative: a strategy for generating a species-level Tree of Life.

Zhou X, Frandsen PB, Holzenthal RW, Beet CR, Bennett KR, Blahnik RJ, Bonada N, Cartwright D, Chuluunbat S, Cocks GV, Collins GE, deWaard J, Dean J, Flint OS Jr, Hausmann A, Hendrich L, Hess M, Hogg ID, Kondratieff BC, Malicky H, Milton MA, Morinière J, Morse JC, Mwangi FN, Pauls SU, Gonzalez MR, Rinne A, Robinson JL, Salokannel J, Shackleton M, Smith B, Stamatakis A, StClair R, Thomas JA, Zamora-Muñoz C, Ziesmann T, Kjer KM.

Philos Trans R Soc Lond B Biol Sci. 2016 Sep 5;371(1702). pii: 20160025. doi: 10.1098/rstb.2016.0025.

17.

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.

Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM.

Oncotarget. 2016 Jul 19;7(29):46492-46508. doi: 10.18632/oncotarget.10216.

18.

A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis.

Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, Koblar S, Harvey NL, Lopez AF, Shackleton M, Bonder CS.

Angiogenesis. 2016 Oct;19(4):463-86. doi: 10.1007/s10456-016-9520-y. Epub 2016 Jun 23.

19.

CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.

Boyle SE, Fedele CG, Corbin V, Wybacz E, Szeto P, Lewin J, Young RJ, Wong A, Fuller R, Spillane J, Speakman D, Donahoe S, Pohl M, Gyorki D, Henderson MA, Johnstone RW, Papenfuss AT, Shackleton M.

Cancer Res. 2016 Jul 1;76(13):3965-77. doi: 10.1158/0008-5472.CAN-15-2377. Epub 2016 Jun 20.

20.

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.

Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G, Sandhu S.

Ann Oncol. 2016 Jun;27(6):1174-7. doi: 10.1093/annonc/mdw056. Epub 2016 Feb 9. No abstract available.

PMID:
26861600
21.

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW.

Cancer Res. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877. Epub 2015 Dec 1.

22.

Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.

Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, Yan H, Lakshmanan M, Koumar RC, Lim ST, Derheimer FA, Campbell RM, Bonday Z, Tergaonkar V, Shackleton M, Blattner C, Marine JC, Guccione E.

J Clin Invest. 2016 Jan;126(1):68-84. doi: 10.1172/JCI82534. Epub 2015 Nov 23.

23.

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, Scolyer RA.

Pathology. 2015 Dec;47(7):683-93. doi: 10.1097/PAT.0000000000000324. Erratum in: Pathology. 2016 Jan;48(1):104.

PMID:
26517638
24.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. No abstract available.

PMID:
26503049
25.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024
26.

Revision of the genus Caenota Mosely (Trichoptera: Calocidae), with descriptions of 2 new species and the larva of C. nemorosa Neboiss.

Shackleton ME, Webb JM.

Zootaxa. 2015 Jun 13;3972(4):451-81. doi: 10.11646/zootaxa.3972.4.1.

PMID:
26249505
27.

Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication.

He M, Lovell J, Ng BL, Spillane J, Speakman D, Henderson MA, Shackleton M, Gyorki DE.

J Surg Oncol. 2015 Jun;111(8):980-4. doi: 10.1002/jso.23938. Epub 2015 Jun 17.

PMID:
26080731
28.

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410. Erratum in: Nature. 2015 Nov 19;527(7578):398.

PMID:
26017449
29.

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB.

Eur J Cancer. 2015 Jul;51(11):1435-43. doi: 10.1016/j.ejca.2015.04.010. Epub 2015 May 13.

30.

Current management of advanced melanoma: a transformed landscape.

Gyorki DE, Spillane J, Speakman D, Shackleton M, Henderson MA.

ANZ J Surg. 2014 Sep;84(9):612-7. doi: 10.1111/ans.12673. Epub 2014 May 20. Review.

PMID:
24842394
31.

Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads.

Schröder J, Hsu A, Boyle SE, Macintyre G, Cmero M, Tothill RW, Johnstone RW, Shackleton M, Papenfuss AT.

Bioinformatics. 2014 Apr 15;30(8):1064-1072. Epub 2014 Jan 2.

32.

Evaluating two infiltration gallery designs for managed aquifer recharge using secondary treated wastewater.

Bekele E, Toze S, Patterson B, Fegg W, Shackleton M, Higginson S.

J Environ Manage. 2013 Mar 15;117:115-20. doi: 10.1016/j.jenvman.2012.12.018. Epub 2013 Feb 4.

PMID:
23380303
33.

Human melanoma metastasis in NSG mice correlates with clinical outcome in patients.

Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR, Johnson TM, Morrison SJ.

Sci Transl Med. 2012 Nov 7;4(159):159ra149. doi: 10.1126/scitranslmed.3004599.

34.

MDM4 is a key therapeutic target in cutaneous melanoma.

Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC.

Nat Med. 2012 Aug;18(8):1239-47. doi: 10.1038/nm.2863. Epub 2012 Jul 22.

35.

Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.

Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA.

PLoS One. 2012;7(5):e36924. doi: 10.1371/journal.pone.0036924. Epub 2012 May 30.

36.

Pulling RANK: are some melanoma cells more malignant than others?

Shackleton M.

J Invest Dermatol. 2011 Apr;131(4):814-6. doi: 10.1038/jid.2011.18.

37.

HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells.

Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell J 4th, Bixby D, Savona MR, Morrison SJ, Collins KL.

Cell Host Microbe. 2011 Mar 17;9(3):223-234. doi: 10.1016/j.chom.2011.02.005.

38.

Behaviour and fate of nine recycled water trace organics during managed aquifer recharge in an aerobic aquifer.

Patterson BM, Shackleton M, Furness AJ, Bekele E, Pearce J, Linge KL, Busetti F, Spadek T, Toze S.

J Contam Hydrol. 2011 Mar 25;122(1-4):53-62. doi: 10.1016/j.jconhyd.2010.11.003. Epub 2010 Nov 25.

PMID:
21186066
39.

Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.

Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ.

Cancer Cell. 2010 Nov 16;18(5):510-23. doi: 10.1016/j.ccr.2010.10.012.

40.

Moving targets that drive cancer progression.

Shackleton M.

N Engl J Med. 2010 Aug 26;363(9):885-6. doi: 10.1056/NEJMcibr1006328. No abstract available.

PMID:
20818851
41.

Melanoma stem cells--are there devils in the detail?

Shackleton M.

Pigment Cell Melanoma Res. 2010 Oct;23(5):693-4. doi: 10.1111/j.1755-148X.2010.00750.x. Epub 2010 Aug 5. No abstract available.

42.

Progress in understanding melanoma propagation.

Shackleton M, Quintana E.

Mol Oncol. 2010 Oct;4(5):451-7. doi: 10.1016/j.molonc.2010.06.006. Epub 2010 Jun 23. Review.

43.

Normal stem cells and cancer stem cells: similar and different.

Shackleton M.

Semin Cancer Biol. 2010 Apr;20(2):85-92. doi: 10.1016/j.semcancer.2010.04.002. Epub 2010 Apr 29. Review.

PMID:
20435143
44.

Fate of nine recycled water trace organic contaminants and metal(loid)s during managed aquifer recharge into a anaerobic aquifer: Column studies.

Patterson BM, Shackleton M, Furness AJ, Pearce J, Descourvieres C, Linge KL, Busetti F, Spadek T.

Water Res. 2010 Mar;44(5):1471-81. doi: 10.1016/j.watres.2009.10.044. Epub 2009 Nov 3.

PMID:
19939429
45.

Use of static Quantitative Microbial Risk Assessment to determine pathogen risks in an unconfined carbonate aquifer used for Managed Aquifer Recharge.

Toze S, Bekele E, Page D, Sidhu J, Shackleton M.

Water Res. 2010 Feb;44(4):1038-49. doi: 10.1016/j.watres.2009.08.028. Epub 2009 Aug 27.

PMID:
19762063
46.

Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Shackleton M, Quintana E, Fearon ER, Morrison SJ.

Cell. 2009 Sep 4;138(5):822-9. doi: 10.1016/j.cell.2009.08.017.

47.

Impaired lactation in mice expressing dominant-negative FADD in mammary epithelium.

Shackleton M, O'Reilly LA, Sutherland KD, Bath ML, Ellis S, Strasser A, Visvader JE, Lindeman GJ.

Dev Dyn. 2009 Apr;238(4):1010-6. doi: 10.1002/dvdy.21917.

48.

Melanoma: do we need a hatchet or a scalpel?

Shackleton MJ, Quintana E, Fullen DR, Sabel MS, Johnson TM.

Arch Dermatol. 2009 Mar;145(3):307-8. doi: 10.1001/archdermatol.2009.3. No abstract available.

PMID:
19289763
49.

Efficient tumour formation by single human melanoma cells.

Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ.

Nature. 2008 Dec 4;456(7222):593-8. doi: 10.1038/nature07567.

50.

Delineating the epithelial hierarchy in the mouse mammary gland.

Asselin-Labat ML, Vaillant F, Shackleton M, Bouras T, Lindeman GJ, Visvader JE.

Cold Spring Harb Symp Quant Biol. 2008;73:469-78. doi: 10.1101/sqb.2008.73.020. Epub 2008 Nov 6. Review.

PMID:
19022771

Supplemental Content

Loading ...
Support Center